tbuckley/cabot-search huggingface dataset:
Endoscopy International Open – recently published
Journal: Endoscopy (2021)

Comment on: Endocuff Vision improves adenoma detection rate in a large screening-related cohortEndosc Int Open 2021; 09(11): E1583-E1592DOI: 10.1055/a-1533-6183 Comment on: Hybrid endoscopic mucosal resection and full-thickness resection for large colonic polyps harboring a small focus of invasive cancer: a case seriesEndosc Int Open 2021; 09(11): E1686-E1691DOI: 10.1055/a-1529-1447 Comment on: Accreditation program for gastrointestinal endoscopes reprocessing in Italy: An on-site surveyEndosc Int Open 2021; 09(11): E1627-E1632DOI: 10.1055/a-1535-1238
<i>ERJ</i>Podcast October 2018: Causal inference studies
Journal: European Respiratory Journal (2018)

As part of the October issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy Chief Editor James Chalmers interviews David Lederer (Editor-in-Chief, Annals of the American Thoracic Society ) about the outcome of a recent discussion among respiratory journal editors on the reporting of causal inference studies.
Dipyridamole myocardial perfusion imaging according to the ACC/AHA guidelines for risk stratification and management of Pts undergoing vascular surgery: A prospective study Pierluigi Pieri, Rossana Berta, Giovanni Moscatelli, Daniele Baccos, Patrizia Ghezzi, Francesco Buccoliero, Jeffrey Leppo. M. Bufalini Hospital, Cesena, Italy
Journal: Journal of the American College of Cardiology (2001)
Unintentional and Undetermined Poisoning Deaths—11 States, 1990-2001
Journal: JAMA (2004)

During 1990-2001, the death rate from poisoning in the United States increased 56%, from 5.0 per 100,000 population in 1990 to 7.8 in 2001. In 2001, of 22,242 poisoning deaths, 14,078 (63%) were unintentional. To describe trends in poisoning deaths, state health professionals in 11 states analyzed vital statistics data for 1990-2001. This report summarizes the results of that analysis, which indicated that increases in state death rates from unintentional and undetermined poisonings varied, but increased by an average of 145%; a total of 89% of poisonings involved drugs and other biologic substances. State public health professionals can use local, state, and national surveillance data to monitor trends in drug misuse and to develop effective interventions that can reduce deaths from drug overdoses.
SHMT1 siRNA-Loaded hyperosmotic nanochains for blood-brain/tumor barrier post-transmigration therapy
Authors: Shambhavi Pandey, Myung Chul Lee, Jae woon Lim, Yun-Hoon Choung, Kyoung-Je Jang, Sang Bae Park, Jae Eun Kim, Jong Hoon Chung, Pankaj Garg
Journal: Biomaterials (2021)
Predictors of long term follow-up after thrombolytic therapy in acute massive pulmonary embolism Marie-France Seronde, Liu Pin Ming, Nicolas Meneveau, Francois Schiele, Luc Doutrelant, Florent Briand, Yvette Bernard, Jean-Pierre L. Bassand. University Hospital Jean-Minjoz, Besancon, France
Journal: Journal of the American College of Cardiology (2001)
Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”
Authors: U.A. Nitz, O. Gluz, M. Christgen, E.-M. Grischke, D. Augustin, S. Kuemmel, M. Braun, J. Potenberg, A. Kohls, K. Krauss, A. Stefek, C. Schumacher, H. Forstbauer, T. Reimer, H. Fischer, C. Liedtke, R. Wuerstlein, J. Schumacher, R. Kates, H. Kreipe, N. Harbeck
Journal: Annals of Oncology (2022)
Doubly resistant gonorrhea looms as future problem
Authors: P. Gunby
Journal: JAMA (1983)

While sexually transmitted herpesvirus infections and acquired immunodeficiency syndrome (AIDS) have been making headlines, there recently have been some equally dramatic developments in connection with the continuing gonorrhea pandemic. The latest concerns spectinomycin hydrochlorideresistant, penicillinase-producing<i>Neisseria gonorrhoeae</i>(PPNG), a double-trouble strain first seen clinically less than two years ago. For what is believed to be the first time, there is confirmation that this doubly resistant organism can be transmitted person-to-person. Such transmission occurred between prostitutes and eight American servicemen stationed in the Pacific (where, in a separate study, a gonorrhea vaccine trial began this year with US military volunteers). Until transmissability was documented, a key question was whether such multiply resistant gonorrhea strains somehow evolved in the already infected host or were transmitted as part of the gonococcal infection. The first time the doubly resistant infection was reported was in late spring of 1981. The patient was a 20-year-old man
TCT-408 Three-year clinical outcome of Everolimus-eluting bioresorbable scaffold vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction - TROFI II trial
Authors: Patrick Serruys, Taku Asano, Salvatore Brugaletta, Lorenz Raber, Yoshinobu Onuma, Stephan Windecker, Manel Sabate
Journal: Journal of the American College of Cardiology (2017)
Age and quality of care provided to elderly patients with acute myocardial infarction Saif S. Rathore, Rajendra H. Mehta, Yongfei Wang, Alan K. Berger, Martha J. Radford, Harlan M. Krumholz. Yale University School of Medicine, New Haven, CT, Qualidigm, Middletown, CT
Journal: Journal of the American College of Cardiology (2001)
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
Authors: Avivit Cahn, Stephen D. Wiviott, Ofri Mosenzon, Erica L. Goodrich, Sabina A. Murphy, Ilan Yanuv, Aliza Rozenberg, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Itamar Raz
Journal: Diabetes Care (2022)

OBJECTIVE Current guidelines recommend prescribing SGLT2 inhibitors to patients with type 2 diabetes and established or at high risk for atherosclerotic cardiovascular disease (ASCVD), irrespective of HbA1c levels. We studied the association of HbA1c with cardiovascular and renal outcomes and whether the benefit of dapagliflozin varies by baseline HbA1c. RESEARCH DESIGN AND METHODS In the Dapagliflozin Effect on Cardiovascular Events trial (DECLARE-TIMI 58), 17,160 patients with type 2 diabetes were randomly assigned to dapagliflozin or placebo for a median follow-up of 4.2 years. Cardiovascular and renal outcomes by baseline HbA1c in the overall population and with dapagliflozin versus placebo in HbA1c subgroups were studied by Cox regression models. RESULTS In the overall population, higher baseline HbA1c was associated with a higher risk of cardiovascular death or hospitalization for heart failure (HHF); major adverse cardiovascular events (MACE), including cardiovascular death, myocardial infarction, and ischemic stroke; and cardiorenal outcomes (adjusted hazard ratios 1.12 [95% CI 1.06–1.19], 1.08 [1.04–1.13], and 1.17 [1.11–1.24] per 1% higher level, respectively). Elevated HbA1c was associated with a greater increased risk for MACE and cardiorenal outcomes in patients with multiple risk factors (MRF) than in established ASCVD (P-interaction = 0.0064 and 0.0093, respectively). Compared with placebo, dapagliflozin decreased the risk of cardiovascular death/HHF, HHF, and cardiorenal outcomes, with no heterogeneity by baseline HbA1c (P-interaction &amp;gt; 0.05). CONCLUSIONS Higher HbA1c levels were associated with greater cardiovascular and renal risk, particularly in the MRF population, yet the benefits of dapagliflozin were observed in all subgroups irrespective of baseline HbA1c, including patients with HbA1c &amp;lt;7%.
Reduced vascular endothelial growth factor receptor but not VEGF production distinguishes ischemic from nonischemic cardiomyopathy Shoukang Zhu, Manisha H. Shah, Christine S. Moravec, Rene Alvarez, Pascal Goldschmidt-Clermont, Philip F. Binkley. The Ohio State University, Columbus, OH, Cleveland Clinic Foundation, Cleveland, OH
Journal: Journal of the American College of Cardiology (2001)
Glutamate in primary afferents is required for itch transmission
Authors: Lian Cui, Jeff Guo, Suna L. Cranfill, Mayank Gautam, Janardhan Bhattarai, William Olson, Katherine Beattie, Rosemary C. Challis, Qinxue Wu, Xue Song, Tobias Raabe, Viviana Gradinaru, Minghong Ma, Qin Liu, Wenqin Luo
Journal: Neuron (2022)
Phase Ib/II trial of siltuximab and spartalizumab in patients in metastatic pancreatic cancer.
Authors: Mehmet Akce, Walid Labib Shaib, Maria Diab, Olatunji B. Alese, Christina Wu, Sunisha Thomas, Emily Greene, Cameron Herting, Gregory B. Lesinski, Bassel F. El-Rayes
Journal: Journal of Clinical Oncology (2022)

TPS626 Background: Interleukin-6 (IL-6) is associated with carcinogenesis, immune suppression, and poor prognosis in pancreatic adenocarcinoma (PDAC). Preclinical data demonstrated dual inhibition of IL-6 and (programmed death ligand-1) PD-L1 facilitates CD8+ T cell migration into pancreatic tumors and was effective in controlling tumor growth in syngeneic and genetically engineered PDAC mouse models. Siltuximab is a chimeric monoclonal antibody which targets the IL-6 molecule specifically and spartalizumab is a high-affinity ligand-blocking humanized IgG4 antibody against the PD-1 receptor. Based on this preclinical rationale, we developed a phase Ib/II trial to determine the recommended phase II dose (RP2D), evaluate the safety, toxicity profile, preliminary antitumor activity, and immunogenicity of the siltuximab and spartalizumab in patients with previously treated metastatic PDAC. Methods: The phase Ib trial design is standard 3+3. Primary endpoint is to determine RP2D. Siltuximab is administered intravenously (IV) in three dose levels of 6 mg/kg (DL1), 11 mg/kg (DL2), 9 mg/kg (only if 2 DLTs observed on DL2) every 3 weeks with spartalizumab at 300 mg IV every 3 weeks. Eligible patients must have stage IV PDAC who have failed at least one prior therapy age ≥18 years, ECOG PS 0-1, no prior anti PD-1 or anti-PD-L1 agent. After RP2D is established, an expansion phase will enroll 24 patients with PDAC. Pre and on-treatment biopsy will be performed in 24 patients in the expansion cohort for correlative analysis. Pre-treatment and on-treatment peripheral blood samples will be collected from all patients. In the expansion phase patients will receive initial cycle (every 3 weeks) treatment with either spartalizumab or spartalizumab plus siltuximab and then starting cycle 2 all patients receive the combination following the on-treatment research biopsy. This design will enable us to evaluate the immunological effects of spartalizumab alone versus the combination in the tumor microenvironment and peripheral blood. This study was activated in January 2020 and to date 12 patients were enrolled in dose escalation phase. The dose expansion phase has recently started accrual. Clinical trial information: NCT04191421.
Tunable Microgel‐Templated Porogel (MTP) Bioink for 3D Bioprinting Applications
Authors: Liliang Ouyang, Jonathan P. Wojciechowski, Jiaqing Tang, Yuzhi Guo, Molly M. Stevens
Journal: Advanced Healthcare Materials (2022)

Abstract Micropores are essential for tissue engineering to ensure adequate mass transportation for embedded cells. Despite the considerable progress made by advanced 3D bioprinting technologies, it remains challenging to engineer micropores of 100 µm or smaller in cell‐laden constructs. Here, a microgel‐templated porogel (MTP) bioink platform is reported to introduce controlled microporosity in 3D bioprinted hydrogels in the presence of living cells. Templated gelatin microgels are fabricated with varied sizes (≈10, ≈45, and ≈100 µm) and mixed with photo‐crosslinkable formulations to make composite MTP bioinks. The addition of microgels significantly enhances the shear‐thinning and self‐healing viscoelastic properties and thus the printability of bioinks with cell densities up to 1 × 10 8 mL −1 in matrix. Consistent printability is achieved for a series of MTP bioinks based on different component ratios and matrix materials. After photo‐crosslinking the matrix phase, the templated microgels dissociated and diffused under physiological conditions, resulting in corresponding micropores in situ. When embedding osteoblast‐like cells in the matrix phase, the MTP bioinks support higher metabolic activity and more uniform mineral formation than bulk gel controls. The approach provides a facile strategy to engineer precise micropores in 3D printed structures to compensate for the limited resolution of current bioprinting approaches.
Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer
Authors: Francesco De Sanctis, Alessia Lamolinara, Federico Boschi, Chiara Musiu, Simone Caligola, Rosalinda Trovato, Alessandra Fiore, Cristina Frusteri, Cristina Anselmi, Ornella Poffe, Tiziana Cestari, Stefania Canè, Silvia Sartoris, Rosalba Giugno, Giulia Del Rosario, Barbara Zappacosta, Francesco Del Pizzo, Matteo Fassan, Erica Dugnani, Lorenzo Piemonti, Emanuela Bottani, Ilaria Decimo, Salvatore Paiella, Roberto Salvia, Rita Teresa Lawlor, Vincenzo Corbo, Youngkyu Park, David A Tuveson, Claudio Bassi, Aldo Scarpa, Manuela Iezzi, Stefano Ugel, Vincenzo Bronte
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest tumors owing to its robust desmoplasia, low immunogenicity, and recruitment of cancer-conditioned, immunoregulatory myeloid cells. These features strongly limit the success of immunotherapy as a single agent, thereby suggesting the need for the development of a multitargeted approach. The goal is to foster T lymphocyte infiltration within the tumor landscape and neutralize cancer-triggered immune suppression, to enhance the therapeutic effectiveness of immune-based treatments, such as anticancer adoptive cell therapy (ACT). Methods We examined the contribution of immunosuppressive myeloid cells expressing arginase 1 and nitric oxide synthase 2 in building up a reactive nitrogen species (RNS)-dependent chemical barrier and shaping the PDAC immune landscape. We examined the impact of pharmacological RNS interference on overcoming the recruitment and immunosuppressive activity of tumor-expanded myeloid cells, which render pancreatic cancers resistant to immunotherapy. Results PDAC progression is marked by a stepwise infiltration of myeloid cells, which enforces a highly immunosuppressive microenvironment through the uncontrolled metabolism of L-arginine by arginase 1 and inducible nitric oxide synthase activity, resulting in the production of large amounts of reactive oxygen and nitrogen species. The extensive accumulation of myeloid suppressing cells and nitrated tyrosines (nitrotyrosine, N-Ty) establishes an RNS-dependent chemical barrier that impairs tumor infiltration by T lymphocytes and restricts the efficacy of adoptive immunotherapy. A pharmacological treatment with AT38 ([3-(aminocarbonyl)furoxan-4-yl]methyl salicylate) reprograms the tumor microenvironment from protumoral to antitumoral, which supports T lymphocyte entrance within the tumor core and aids the efficacy of ACT with telomerase-specific cytotoxic T lymphocytes. Conclusions Tumor microenvironment reprogramming by ablating aberrant RNS production bypasses the current limits of immunotherapy in PDAC by overcoming immune resistance.
Bridge-to-transplant stereotactic body radiation therapy in patients with hepatocellular carcinoma and advanced cirrhosis.
Authors: Mohammad Hissourou, Khashayar Farsad, C. Kristian Enestvedt, Alice Fung, Barry Schlansky, Willscott E Naugler, Nima Nabavizadeh
Journal: Journal of Clinical Oncology (2022)

TPS496 Background: Liver cancer is the third most common cause of cancer related death worldwide, and hepatocellular carcinoma (HCC) accounts for 90% of all primary liver cancers, with pre-existing cirrhosis being a very strong risk factor for HCC development. Liver transplantation (LTx) is the best treatment for patients with HCC and advanced cirrhosis as both conditions can be very effectively treated at once. As LTx wait-lists can be many months, liver-directed therapies (LDT), including stereotactic body radiation therapy (SBRT) to one or few lesions are essential as oncologic temporizing measures to bridge patients to LTx and prevent progression outside of LTx criteria. However, due to the fear of further hepatic decompensation, many patients with advanced cirrhosis are excluded from receiving LDT. Rather, recent studies suggest that SBRT be of safe and practical use in this fragile patient population with advanced cirrhosis and HCC, and thereby reduce the rate of transplantation drop-out. This pilot prospective study will assess the feasibility, safety and efficacy of bridge-to-transplantation SBRT for patients with advanced cirrhosis and HCC. Methods: Patients with non-metastatic and unresectable HCC and Child-Pugh (CP)-B8 or worse cirrhosis who are within Milan criteria (one tumor ≤ 5 cm in diameter or no more than 3 tumors each ≤ 3 cm in diameter) and have been listed or recommended to be listed for liver transplantation will be eligible for participation. Eligible participants will undergo SBRT consisting of 40 Gy to be given in 5 fractions every other day to the only or largest lesion, provided that criteria for normal organ constraints are met. In cases where normal organ constraints are not met, the dose will be iteratively de-escalated to two dose levels (35 Gy in 5 fractions, then 30 Gy in 5 fractions). If normal organ constraints are unable to be met at 30 Gy in 5 fractions, the participant will be considered ineligible for SBRT and considered a screen failure. The primary endpoint is the proportion of participants who are transplanted or with localized disease control that meets Milan criteria within a year of SBRT. Secondary endpoints will include localized control rate (mRECIST), incidence of intra- or extra-hepatic progressive disease (mRECIST), overall survival, incidence of liver toxicity per CTCAE v5.0, incidence of non-classical radiation-induced liver disease (defined as CTCAE grade 4 AST/ALT elevation or an increase in CP score of ≥ 2 within 3 months of SBRT) and quality of life scores per QLQ-C30 and FACT-Hep questionnaires. The study is open, aiming to enroll 15 patients with 8 patients enrolled at time of submission. Clinical trial information: NCT03812289.
Right ventricular function in severe pulmonary hypertension due to congenital or acquired heart disease: Is there a difference? Christine H. Attenhofer Jost, Andre Z. Linka, Friedrich Maly, Christoph Schalcher, Erwin Oechslin, Rolf Jenni. Division of Cardiology, University Hospital, Zurich, Switzerland
Journal: Journal of the American College of Cardiology (2001)
Erratum
Journal: JNCI Journal of the National Cancer Institute (1994)

“Surprising Activity of Flutamide Withdrawal, When Combined With Aminoglutethimide, in Treatment of ‘Hormone-Refractory’ Prostate Cancer,” by O. Sartor, M. Cooper, M. Weinberger, et al. [J Natl Cancer Inst 86:222-227, 1994 (Issue 3)]. The authors wish to correct an error in the second sentence of paragraph three on page 226. The sentence should read, “When aminoglutethimide was administered to patients who had been pretreated with suramin and hydrocortisone in the absence of simultaneous flutamide withdrawal, fewer than 5% of patients had a decline in PSA levels of more than 80% (Sartor O, Eisenberger MA: unpublished data).”
Abstract P273: Longitudinal Association Between Body Weight Change and 6-year Change of Blood Pressure in Japanese Men
Authors: Shin-ya Nagasawa
Journal: Circulation (2017)

Objective: Overweight is associated with increases in the risks of hypertension and cardiovascular disease. However, long-term and especially repeated measures analysis about relationship between body weight (BW) change and blood pressure (BP) change is only a little. We investigate the longitudinal relationship between BW change and years-long change of BP in a prospective cohort study. Participants: A total of 2546 male employees aged 25-53 years without use of antihypertensive drug in a metal products factory in Japan. Measurements: The BP was annually measured once in the right arm after 5 min of rest in a seated position, by well-trained nurses using a standard mercury sphygmomanometer from 2003 (baseline) to 2009. Physical examinations and information on lifestyle and use of medicine were annually measured or confirmed during the same period. The associations between difference of BW from 2003 to 2008 and 6-years change of systolic and diastolic BP from 2003 to 2009 were analyzed with generalized estimating equation models. Covariates in full adjusted model were age, body mass index, and smoking and drinking status in baseline. Results: Mean ± standard deviation (SD) of age, height, and BW in 2003 was 39.3 ± 8.0 years, 170.6 ± 6.0 cm, and 68.2 ± 9.9 kg, respectively. Mean ± SD of BW in 2008 was 68.8 ± 10.2 kg. Mean ± SD of systolic and diastolic BP in 2003 were 119.7 ± 14.6 and 74.3 ± 11.3 mmHg, respectively. Systolic and diastolic BP in 2009 were 120.5 ± 15.1 and 76.4 ± 10.9 mmHg, respectively. In full adjusted model, 1 kg increase of BW in 5 years was significantly associated with 0.17 mmHg higher systolic BP ( P = 0.024) and 0.113 mmHg diastolic BP ( P = 0.012) in 6 years. Conclusions: Beyond relevant covariates, increasing BW significantly elevated both systolic and diastolic BP.
Brain metastasis in gastroesophageal adenocarcinoma: Outcomes and molecular features.
Authors: Charlton Tsai, Bastien Nguyen, Anisha Luthra, Joanne F. Chou, Laura H. Tang, Vivian E. Strong, Daniela Molena, David Randolph Jones, Daniel G. Coit, David H. Ilson, Geoffrey Yuyat Ku, Nelson S. Moss, Kathryn Beal, Marinela Capanu, Nikolaus Schultz, Yelena Y. Janjigian, Steven Brad Maron
Journal: Journal of Clinical Oncology (2022)

347 Background: Brain metastases (BrM) rarely occur in patients with metastatic gastroesophageal adenocarcinoma (GEA) and represent a unique therapeutic challenge. We describe the unique clinical, molecular, and genomic factors associated with mGEA cancer and BrM development in order to help guide future clinical management. Methods: Patients (pts) with GEA seen at Memorial Sloan Kettering Cancer Center (MSKCC) from 2008-2019 and who had consented for genomic tumor profiling with MSK-IMPACT, a capture-based next-generation sequencing platform that detects mutations, copy-number variations, and select fusions, were retrospectively identified. Clinical and pathologic characteristics were reviewed. BrM were identified via International Classification of Diseases (ICD) billing codes and electronic medical record problem lists, and then manually validated. Survival was calculated from the time of BrM diagnosis until date of death or last follow up and estimated using the Kaplan-Meier method. Results: Fifty pts with GEA metastatic to the brain were identified. Most pts were male (86%) and white (80%), with primary tumor of the esophagus/gastroesophageal junction (82%) and intestinal-type Lauren histology (90%). Twenty-three pts (46%) were HER2 positive (defined as IHC 2+/FISH+ or IHC 3+). Frequencies of PTEN (16%) and EGFR (22%) alterations in primary or metastatic sites were enriched in pts with BM compared to that seen across the MSKCC retrospective cohort and the GEA Cancer Genome Atlas (TCGA) cohort. The majority (68%) of pts had stage IV disease at initial diagnosis, and 4 pts were found to have BrM within 1 month (mo) of stage IV diagnosis, while 27 pts developed BrM during therapy. Median time to BrM diagnosis was 18.3 mos (IQR 11.5-28.9) and 15.1 mos from stage IV diagnosis (IQR 4.8-25.5). Median survival was 7.6 mos from BrM diagnosis and 15.6 (95% CI 10.0-NR, n = 19), 7.6 (95% CI 2.5-NR, n = 13), and 4.3 (95% CI 3.5-12.3, n = 18) mos for pts with 1, 2-3, or 4+ BrM, respectively. Conclusions: GEA pts with BrM had increased frequency of HER2 positivity, as well as PTEN and EGFR alterations, compared to GEA pts overall historically. Further correlation between BrM development, molecular characteristics, and survival in a larger cohort will be presented.